PharmacologyTier 1Medical Sciences concept

All-trans retinoic acid - differentiation syndrome

Core concept

  • ATRA (all-trans retinoic acid) treats acute promyelocytic leukaemia (APL, AML M3) by forcing terminal differentiation of the malignant promyelocyte clone (targets the PML-RARA fusion product)
  • Differentiation syndrome: massively differentiating leukocytes release inflammatory cytokines -> capillary leak -> multi-organ involvement
  • Occurs in ~15-25% of APL patients started on ATRA (or arsenic trioxide), typically within the first 2-3 weeks

3 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.

Get premium access